Named on one round in the feed.
Since 2025-01-08
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Aspect Biosystems Bioengineered cellular medicines aimed at transforming disease treatment using bioprinting technology and regenerative medicine. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-01-08 | [ PART ] |